Logo

CHE

Chemed Corporation

CHE

Chemed Corporation • NYSE
$439.19 ▼ -0.49% (-2.17)
Market Cap $6.42 B
52w High $623.61
52w Low $408.42
Dividend Yield 2.20%
P/E 23.25
Volume 71.27K
Outstanding Shares 14.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $624.9M ▲ $105.775M ▼ $64.237M ▲ 10.28% ▲ $4.46 ▲ $101.779M ▲
Q2-2025 $618.798M ▼ $116.609M ▼ $52.493M ▼ 8.483% ▼ $3.6 ▼ $87.818M ▼
Q1-2025 $646.943M ▲ $121.655M ▲ $71.757M ▼ 11.092% ▼ $4.91 ▼ $112.02M ▼
Q4-2024 $639.993M ▲ $120.24M ▲ $90.319M ▲ 14.112% ▲ $6.08 ▲ $136.453M ▲
Q3-2024 $606.181M $117.837M $75.776M 12.501% $5.04 $117.153M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $129.752M ▼ $1.624B ▼ $546.936M ▲ $1.077B ▼
Q2-2025 $249.904M ▲ $1.718B ▼ $519.362M ▼ $1.198B ▲
Q1-2025 $173.882M ▼ $1.727B ▲ $544.753M ▼ $1.182B ▲
Q4-2024 $178.35M ▼ $1.669B ▼ $549.582M ▲ $1.119B ▼
Q3-2024 $238.451M $1.769B $533.68M $1.236B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $64.237M ▲ $83.389M ▼ $-14.234M ▲ $-189.307M ▼ $-120.152M ▼ $66.03M ▼
Q2-2025 $52.493M ▼ $138.606M ▲ $-15.481M ▼ $-47.103M ▼ $76.022M ▲ $122.798M ▲
Q1-2025 $71.757M ▼ $32.744M ▼ $-13.674M ▼ $-23.538M ▲ $-4.468M ▲ $19.464M ▼
Q4-2024 $90.319M ▲ $164.913M ▲ $-12.52M ▲ $-212.494M ▼ $-60.101M ▼ $152.152M ▲
Q3-2024 $75.776M $90.518M $-18.517M $-56.453M $15.548M $76.973M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Segment Roto Rooter
Segment Roto Rooter
 $0 ▲$250.00M ▲$230.00M ▼$230.00M ▲
Segment Vitas
Segment Vitas
 $0 ▲$420.00M ▲$420.00M ▲$420.00M ▲
All Other Revenue Self Pay Respite Care Ect
All Other Revenue Self Pay Respite Care Ect
 $10.00M ▲$0 ▼$0 ▲$0 ▲
Care Services Total
Care Services Total
 $420.00M ▲$0 ▼$0 ▲$0 ▲
Continuous Care
Continuous Care
 $30.00M ▲$0 ▼$0 ▲$0 ▲
Inpatient Care
Inpatient Care
 $30.00M ▲$0 ▼$0 ▲$0 ▲
Routine Home Care
Routine Home Care
 $360.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Chemed’s income statement shows a business that is both steady and profitable. Revenue has trended upward over the past five years, not explosively but consistently, which is often a sign of durable demand in its core hospice and plumbing services. Profitability at each level — gross, operating, and net — has stayed strong and fairly stable, suggesting good cost control and pricing power. Earnings per share have been high and generally rising over time, though not in a straight line, which is typical for a company operating in regulated healthcare and emergency services. Overall, the income statement reflects a mature company with dependable earnings rather than a volatile growth story.

Balance Sheet

Balance Sheet The balance sheet looks conservative and has strengthened over time. Total assets have grown while shareholders’ equity has increased meaningfully, indicating that profits are being retained and reinvested rather than relying heavily on borrowing. Debt levels are modest and have come down from earlier peaks, which reduces financial risk and gives the company flexibility if conditions worsen. Cash balances move around year to year, but there is no sign of liquidity stress. In simple terms, Chemed’s financial foundation appears solid, with low leverage and a growing equity cushion.

Cash Flow

Cash Flow Cash generation is a key strength. Operating cash flow has consistently covered not only day‑to‑day needs but also capital spending with room to spare, leading to solid free cash flow year after year. Capital spending requirements are relatively modest, which is typical of asset‑light service businesses like hospice care and plumbing. This combination — strong, repeatable cash inflows and limited investment needs — gives Chemed options: it can fund growth, manage through downturns, and return cash to shareholders without stretching its finances. The only caution is that cash flows can fluctuate with policy changes, reimbursement dynamics, and macro conditions, but the five‑year pattern is clearly resilient.

Competitive Edge

Competitive Edge Chemed has an unusually strong competitive position built on two leaders in very different but essential service markets. VITAS is a top hospice provider nationally, benefiting from its scale, deep relationships with hospitals and physicians, and expertise in handling complex, high‑acuity patients that smaller players often cannot accommodate. Roto‑Rooter is a household name in plumbing and drain services, with a brand that many consumers recognize first in emergencies. Both markets are fragmented, and Chemed’s national reach, 24/7 service capabilities, and broad service menus create meaningful barriers for local competitors. The dual‑business structure also spreads risk: hospice is more exposed to regulation and reimbursement policy, while plumbing and restoration are more tied to housing and commercial activity. Key risks include potential Medicare reimbursement changes, staffing and wage pressures in healthcare, and ongoing competition from local service providers, but the overall moat appears wide and durable.

Innovation and R&D

Innovation and R&D Chemed’s innovation focus is practical and service‑oriented rather than flashy. VITAS invests in digital tools that streamline care — mobile apps for clinicians, electronic health records at the bedside, telecare, and experiments with virtual reality to improve patient comfort. Partnerships with specialized software providers aim to tighten workflows and coordination across large care teams. On the Roto‑Rooter side, the company maintains proprietary equipment, advanced camera inspection tools, modern water‑restoration technology, and sophisticated dispatch systems to keep technicians productive and response times short. Looking ahead, there is clear emphasis on telehealth, data analytics, and potential smart‑home plumbing services. While Chemed is not a traditional “R&D‑heavy” company, its ongoing incremental innovation is tightly aligned with efficiency, customer experience, and maintaining its lead in both segments.

Summary

Overall, Chemed presents as a resilient, cash‑generative company with two strong, recession‑resistant service franchises. Financial results over the past five years point to steady growth, robust margins, and a strengthening balance sheet with low reliance on debt. Its competitive advantages stem from scale, brand strength, and operational know‑how in both hospice care and plumbing/restoration, supported by targeted use of technology rather than headline‑grabbing research projects. The main uncertainties are external: healthcare reimbursement policy, labor availability and wage inflation in clinical roles, and competitive pressure from local providers in both businesses. Within that context, Chemed appears well positioned to continue generating stable earnings and cash, with room to invest in technology, tuck‑in acquisitions, and service expansion as opportunities arise.

NEWS

November 7, 2025 · 11:28 AM UTC

Chemed Corporation Declares Quarterly Dividend of 60 Cents

Read more

November 4, 2025 · 12:00 PM UTC

Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference

Read more

October 28, 2025 · 4:15 PM UTC

Chemed Reports Third-Quarter 2025 Results

Read more

October 1, 2025 · 12:00 PM UTC

Chemed To Report Third-Quarter 2025 Earnings October 28, Related Conference Call To Be Held On October 29

Read more

September 23, 2025 · 12:00 PM UTC

Chemed Corporation to Present at the Jefferies 2025 Healthcare Services Conference

Read more